Voyager Therapeutics (VYGR) Non Operating Income (2014 - 2026)
Voyager Therapeutics (VYGR) posted Non Operating Income of $2.3 million for Q1 2026, up 11.18% sequentially from $2.1 million in Q4 2025, and down 36.72% YoY from $3.7 million in Q1 2025.
Voyager Therapeutics (VYGR) Non Operating Income (2014 - 2026) Analysis & Trends
Voyager Therapeutics has reported Non Operating Income for 13 years, with the latest figure at $2.3 million in Q1 2026.
- Quarterly Non Operating Income fell 36.72% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.5 million (down 41.7% YoY) and the FY2025 annual result came in at $10.6 million, down 43.97% from the prior year.
- Non Operating Income climbed to $2.3 million in Q1 2026 per VYGR's latest filing, from $2.1 million in the prior quarter.
- Over five years, Non Operating Income peaked at $4.9 million in Q2 2024 and troughed at $31000.0 in Q1 2022.
- A 5-year average of $2.8 million and a median of $3.2 million in 2023 frame the typical range for Non Operating Income.
- The widest YoY moves for Non Operating Income: up 5955.56% in 2022, down 99.21% in 2022.
- Over 5 years, Non Operating Income stood at $953000.0 in 2022, then surged by 230.95% to $3.2 million in 2023, then surged by 46.35% to $4.6 million in 2024, then plunged by 54.27% to $2.1 million in 2025, then gained by 11.18% to $2.3 million in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $2.3 million, $2.1 million, and $2.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -53.64 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | - |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | -51.63 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Voyager Therapeutics | 201.32 Mn | 84.98 Mn | - | 1.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.94 Mn |
| Mar 31, 2026 | 2.35 Mn |
| Dec 31, 2025 | 2.11 Mn |
| Sep 30, 2025 | 2.79 Mn |
| Jun 30, 2025 | 3.26 Mn |
| Mar 31, 2025 | 3.71 Mn |
| Dec 31, 2024 | 4.62 Mn |
| Sep 30, 2024 | 4.78 Mn |
| Jun 30, 2024 | 4.91 Mn |
| Mar 31, 2024 | 4.87 Mn |
| Dec 31, 2023 | 3.15 Mn |
| Sep 30, 2023 | 3.43 Mn |
| Jun 30, 2023 | 3.27 Mn |
| Mar 31, 2023 | 1.86 Mn |
| Dec 31, 2022 | 953,000.00 |
| Sep 30, 2022 | 545,000.00 |
| Jun 30, 2022 | 219,000.00 |
| Mar 31, 2022 | 31,000.00 |
| Dec 31, 2021 | 2.17 Mn |
| Sep 30, 2021 | 9,000.00 |